Federation des caisses Desjardins du Quebec’s Acrivon Therapeutics ACRV Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$556	Hold	400	–	–	﹤0.01%	2811
2025 Q4	$964	Hold	400	–	–	﹤0.01%	2680
2025 Q3	$724	Hold	400	–	–	﹤0.01%	2698
2025 Q2	$476	Hold	400	–	–	﹤0.01%	2580
2025 Q1	$812	Hold	400	–	–	﹤0.01%	2442
2024 Q4	$2.41K	Hold	400	–	–	﹤0.01%	2209
2024 Q3	$2.8K	Hold	400	–	–	﹤0.01%	2184
2024 Q2	$2.32K	Buy	+400	New	+$3.22K	﹤0.01%	2089

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's ACRV Position: Q1 2026 in Review

Federation des caisses Desjardins du Quebec held its Acrivon Therapeutics (ACRV) position steady in Q1 2026 at 400 shares worth $556. The position accounts for ﹤0.01% of the portfolio, ranked #2811.

Federation des caisses Desjardins du Quebec first reported a position in ACRV in Q2 2024 and has held it in 8 quarters since. The position peaked at $2.8K in Q3 2024. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Federation des caisses Desjardins du Quebec held 400 shares of Acrivon Therapeutics worth $556 as of Q1 2026.
Federation des caisses Desjardins du Quebec left its Acrivon Therapeutics share count unchanged in Q1 2026.
Acrivon Therapeutics made up ﹤0.01% of Federation des caisses Desjardins du Quebec's portfolio in Q1 2026, its #2811 holding.
Federation des caisses Desjardins du Quebec first reported a position in Acrivon Therapeutics in Q2 2024 and has held it in 8 quarters since.
Federation des caisses Desjardins du Quebec's Acrivon Therapeutics position peaked at $2.8K in Q3 2024.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2026, filed 14 May 2026.